(NewsDirect)
Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD JoelLatham sits down with Proactive to talk about the development andmanufacturing deal it has struck with pharma giant Catalent to produceits own psilocybin drug. The product would initially be deployed inIHL’s clinical development program for generalised anxiety disorder,but there are plans down the track for its commercial use or supply asa cGMP pharmaceutical-grade therapy.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.